STEVEN PRUDENCIO: Open Payments
NPI 1811366545 · ROSEBURG, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,091 in 37 payments from 18 companies in 2025. Trend: 2023 $50 · 2024 $420 · 2025 $1,091
Food & beverage: $1,091
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $288 |
| Axsome Therapeutics, Inc. | 4 | $172 |
| ABBVIE INC. | 5 | $125 |
| Novo Nordisk Inc | 4 | $87 |
| PFIZER INC. | 3 | $60 |
| REVANCE THERAPEUTICS, INC. | 1 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Edwards Lifesciences Corporation | 1 | $35 |
| GlaxoSmithKline, LLC. | 1 | $33 |
| Amgen Inc. | 1 | $32 |
Products named: Auvelity, AIRSUPRA, FARXIGA, UBRELVY, DAXXIFY, Ozempic, VRAYLAR, NURTEC ODT.
Industry payments across OR — which companies pay providers there.
